Mpox is a virus spread mostly through close, intimate contact with someone who has already contracted the virus. Currently, HHS – through the Centers of Disease Control and Prevention – is tracking an outbreak of mpox that has spread across several countries that don’t normally report mpox, including the United States.
As part of the whole-of-government approach to tackling mpox, HHS is working closely with public health officials and other key stakeholders to ensure high-risk communities in localities across the country get vaccines, testing, and treatments.
White House National Mpox Response Deputy Coordinator, Dr. Demetre Daskalakis, answers some questions on mpox vaccines, including the intradermal route for the JYNNEOS vaccine. Prior to being appointed as Deputy Coordinator, Dr. Daskalakis served as Director of the CDC Division of HIV Prevention and is a national expert on health issues affecting the LGBTQI+ community.
NOTE: On November 28, 2022, The World Health Organization announced the name “mpox” is to replace what was previously referred to as “monkeypox.” This site has been updated to reflect this change, while some material created prior to the change may still reflect the old name.
Important Mpox Information from Around the Department
Learn how the Administration for Strategic Preparedness and Response (ASPR) is delivering mpox vaccines to public health partners in states and major metropolitan areas across the country.
Learn how the U.S. Food and Drug Administration (FDA) facilitates the development and availability of tests, treatments, and vaccines for mpox, as well as authorizes certain medical products to combat the virus for emergency use.
Find out how much TPOXX is being made available to jurisdictions nationwide for the treatment of individuals infected with mpox under Expanded Access Investigational New Drug (EA-IND).
This document provides answers to frequently asked questions about coverage for mpox vaccine administration, particularly when provided by pharmacists.